Silent Method
New member
Hehe. I haven't been on the anabolic board in a bit and this is what I come back to? I like this thread.
First thing, let me say flat out - I like "big" doses. That is, playing around with small doses is short-changing yourself in terms of the ratio of side effects and gains.
However, I think it is short-sided to proclaim that doubiling any dose will double the gains.
The study cited only examines supraphysiological doses up to 600mg/week. I have seen at least two studies which found that the accelerated anabolic effects of exogenous testosterone on healthy, athletically trained males basically doesn't even come on-line untill around 500mg/week as opposed to a lower dosage.
In a system as dynamic and complex as the human body, concluding that a given dosage of a compound will impart a response in a fixed linear ratio to all possible dosages, simply because the equation works at some level, is absurd.
Perhaps this theory holds up in the case of 300 mg to 600 mg. This does not mean that the dosage/response ratio will remain linear with higher dosages.
First thing, let me say flat out - I like "big" doses. That is, playing around with small doses is short-changing yourself in terms of the ratio of side effects and gains.
However, I think it is short-sided to proclaim that doubiling any dose will double the gains.
The study cited only examines supraphysiological doses up to 600mg/week. I have seen at least two studies which found that the accelerated anabolic effects of exogenous testosterone on healthy, athletically trained males basically doesn't even come on-line untill around 500mg/week as opposed to a lower dosage.
In a system as dynamic and complex as the human body, concluding that a given dosage of a compound will impart a response in a fixed linear ratio to all possible dosages, simply because the equation works at some level, is absurd.
Perhaps this theory holds up in the case of 300 mg to 600 mg. This does not mean that the dosage/response ratio will remain linear with higher dosages.